Bispecific Antibodies

Q: IgG-like vs. tandem scFv—which to choose?

IgG-like offers extended half-life and stability; tandem scFv is compact and ideal for TCEs. For better process stability, consider scFv-Fc or DART-like formats.

Q: What is the optimal CD3 affinity?

Moderate CD3 affinity is typically preferred to achieve effective T-cell activation while minimizing background. Use EC50 and cytokine release data from cell models to guide selection.

Q: Do these have Fc effector function?

Both Fc-silent and effector-enhanced versions are available. Fc-silent is standard for CD3 TCEs; effector-enabled can be selected for dual-blockade or ADCC/ADCP studies.

Q: RUO disclaimer

All products are for Research Use Only (RUO) and not intended for diagnostic or therapeutic procedures.

Home > Products > Antibodies > Bispecific Antibodies

abinScience bispecific antibodies (bsAbs) enable T-cell redirection and simultaneous pathway blockade. We provide IgG-like architectures (e.g., knob-into-hole/CrossMab-style), tandem scFv “BiTE-like” constructs, DART-like/scFv-Fc formats, and VHH-based bispecifics. Each lot includes dual-binding ELISA/BLI data and, where applicable, cell-based activity (e.g., CD3×TAA cytotoxicity or checkpoint dual-blockade), plus SEC-HPLC and endotoxin reporting. RUO

Why Researchers Choose abinScience

Diverse Formats IgG-like, BiTE-like, DART, scFv-Fc, VHH

Mechanism Panels CD3×TAA, checkpoint dual blockers

Fc Options Effector-silent or effector-enabled

Rigorous QC Dual-binding, competition, SEC-HPLC, low endotoxin

Lot-Specific CoA Handling & storage guidance

Shop by Mechanism

Shop by Format

Selection Guide

Mechanism: Choose CD3×TAA for T-cell redirection vs. dual-blockade or receptor co-targeting for pathway modulation.
Format: IgG-like for extended half-life/handling; tandem scFv for compact TCE designs; scFv-Fc/DART-like for balance of size and stability.
Fc Design: Use effector-silent Fc for CD3 engagers to minimize off-target FcγR effects; enable Fc if ADCC/ADCP is part of your hypothesis.
Affinity & Arm Balance: Verify KD/EC50 for both arms; avoid excessive CD3 affinity that may increase background activation.
Controls: Include monospecific parents, non-binding isotype, and arm-swapped controls; confirm dual-binding by orthogonal methods.

Applications

T-cell redirection cytotoxicity assays (CD3×TAA)

Checkpoint co-blockade synergy and signaling studies

Receptor cross-linking, internalization and trafficking

Binding kinetics and competition profiling (SPR/BLI/ELISA)

Documents & QC

Dual-binding ELISA/BLI and competition data

Cell-based activity (where applicable), acceptance criteria

SEC-HPLC purity/aggregation; endotoxin (LAL); storage guidance

FAQs

IgG-like vs. tandem scFv—which to choose?

IgG-like offers extended half-life and stability; tandem scFv is compact and ideal for TCEs. For better process stability, consider scFv-Fc or DART-like formats.

What is the optimal CD3 affinity?

Moderate CD3 affinity is typically preferred to achieve effective T-cell activation while minimizing background. Use EC50 and cytokine release data from cell models to guide selection.

Do these have Fc effector function?

Both Fc-silent and effector-enhanced versions are available. Fc-silent is standard for CD3 TCEs; effector-enabled can be selected for dual-blockade or ADCC/ADCP studies.

RUO disclaimer

All products are for Research Use Only (RUO) and not intended for diagnostic or therapeutic procedures.

Options+